All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Impact of baseline gene mutations on quizartinib survival benefits in patients with FLT3-ITD+ AML: Post hoc analysis of the QuANTUM-First trial
Bookmark this article
|
During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, Levis presented results from an exploratory post hoc analysis of the phase III QuANTUM-First trial (NCT02668653) evaluating the impact of co-mutations on survival benefits with quizartinib in patients with FLT3-ITD+ ND AML.1 |
| Key learnings |
| Among 518 evaluable patients with FLT3-ITD+ AML, mutations were detected in 96.5%, with NPM1 (54%) and DNMT3A (43%) being the most common. NPM1 and DNMT3A were co-mutated in 32% of patients. |
| Quizartinib demonstrated substantial survival benefits across most mutational subgroups, including NPM1 (mOS: NE vs 15.1 months; mRFS: 48.6 vs 12.6 months) and DNMT3A (mOS: 40.4 vs 9.6 months; mRFS: 48.6 vs 8.5 months). Survival benefits with quizartinib vs placebo were most pronounced in patients harboring triple mutations (FLT3-ITD + NPM1 + DNMT3A), with mOS of NE vs 9.6 months and mRFS of 48.6 vs 7.1 months. |
| CRc rates were similar with quizartinib vs placebo in patients with NPM1 (85% vs 82%) and DNMT3A (77% vs 69%) mutations, indicating absence of primary resistance to quizartinib due to baseline mutations. |
| In the QuANTUM-First trial, quizartinib consistently improved survival in patients with ND FLT3-ITD+ AML vs placebo, irrespective of co-occurring baseline mutations. |
Abbreviations: AML, acute myeloid leukemia; CRc, composite CR (complete remission [CR] or CR with incomplete blood count recovery [CRi]); ITD, internal tandem duplications; m, median; ND, newly diagnosed; NE, not evaluable; OS, overall survival; RFS, relapse-free survival.
- Levis MJ. Correlation of baseline gene mutations with quizartinib efficacy in patients with FLT3-ITD–positive newly diagnosed acute myeloid leukemia in the phase 3 QuANTUM-First trial. Oral abstract #848. 66th American Society of Hematology Annual Meeting and Exposition; Dec 7–10, 2024; San Diego, US.
Your opinion matters
35 votes - 22 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox